Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- FARON.HE
- Price
- 0.55
- Stock movement down
- -0.06 (-9.54%)
- Company name
- Faron Pharmaceuticals Oy
- Exchange
- (HE ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 63.68M
- Ent value
- 82.60M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-03-10
DIVIDENDS
FARON.HE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 115.78M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | 0.00 |
| Net income (TTM) | 0.00 |
| EPS (TTM) | - |
| EPS (1y forward) | -0.22 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 13.53M |
| Net receivables | 0.00 |
| Total current assets | 14.80M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 250.00K |
| Total assets | 16.20M |
| Accounts payable | 5.63M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 7.83M |
| Total liabilities | 32.45M |
| Shareholder's equity | -16.25M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 0.00 |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | 0.00 |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.61 |
| Daily high | 0.62 |
| Daily low | 0.54 |
| Daily Volume | 2.06M |
| All-time high | 2.40 |
| 1y analyst estimate | 2.24 |
| Beta | 1.09 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 4 Mar 2026 |
Downside potential
Loading...
Downside potential data
| FARON.HE | S&P500 | |
| Current price drop from All-time high | -77.13% | -1.82% |
| Highest price drop | -77.13% | -56.47% |
| Date of highest drop | 17 Feb 2026 | 9 Mar 2009 |
| Avg drop from high | -14.16% | -10.84% |
| Avg time to new high | 10 days | 12 days |
| Max time to new high | 65 days | 1805 days |
COMPANY DETAILS
Marketcap
63.68M
Marketcap category
Small-cap
Description
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. In addition, it develops receptors involved in regulation of immune response in organ damage and bone marrow regeneration. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
Employees
32
Website
Investor relations
-
SEC filings
CEO
Country
Finland
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Great Southern Copper, Sunda Energy, Faron Pharmaceuticals, Astrid Intelligence, Bellevue Healthcare
Great Southern Copper PLC (LSE:GSCU, FRA:E9E) has hit big in Chile. A step-out hole returned up to 6.55% copper and 320 grams per tonne silver. The results suggest the Mostaza Fault Zone is bigger tha...
March 10, 2026
TURKU, FINLAND / ACCESS Newswire / March 9, 2026 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunother...
March 9, 2026
Faron Pharmaceuticals Oy (FRA:4FR) reports promising clinical results but faces financial hurdles as it plans for future trials.
March 4, 2026
The Annual Report 2025 published did not contain the auditor's report. This has been corrected in this version. TURKU, FINLAND / ACCESS Newswire / March 4, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE...
March 4, 2026
TURKU, FI / ACCESS Newswire / March 4, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today ...
March 4, 2026
TURKU, FI / ACCESS Newswire / March 4, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Continued steady progress with bexmarilimab and solidifying position as a leading macrophage based immunothe...
March 4, 2026
TURKU, FI / ACCESS Newswire / March 2, 2026 / Faron Pharmaceuticals Ltd (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announc...
March 2, 2026
Building on the clinical results of the BEXMAB trial, the IIT aims to evaluate bexmarilimab with an oral HMA backbone to further strengthen evidence of its efficacy in research participants with high-...
March 2, 2026
Faron's Bexmarilimab Data Accepted for Poster Presentation at the BSH Annual Scientific Meeting 2026
TURKU, FI / ACCESS Newswire / February 23, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies...
February 23, 2026
Trial investigates macrophage re-reprogramming immunotherapy bexmarilimab in combination with azacitidine to prevent relapse in MRD-positive AML after stem cell transplantation. TURKU, FI / ACCESS New...
February 19, 2026
Next page